Stemline Therapeutics, Inc.
STML
STML was delisted on the 9th of June, 2020.
80 hedge funds and large institutions have $236M invested in Stemline Therapeutics, Inc. in 2017 Q4 according to their latest regulatory filings, with 13 funds opening new positions, 28 increasing their positions, 22 reducing their positions, and 11 closing their positions.
65% more capital invested
Capital invested by funds: $143M → $236M (+$92.9M)
46% more call options, than puts
Call options by funds: $2.07M | Put options by funds: $1.41M
27% more repeat investments, than reductions
Existing positions increased: 28 | Existing positions reduced: 22
18% more first-time investments, than exits
New positions opened: 13 | Existing positions closed: 11
1% more funds holding
Funds holding: 79 → 80 (+1)
Top Buyers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
CCM
Consonance Capital Management
New York
|
+$30.1M |
| 2 |
Adage Capital Partners
Boston,
Massachusetts
|
+$10.4M |
| 3 |
IBT
International Biotechnology Trust
London,
United Kingdom
|
+$4.15M |
| 4 |
LSC
Lyon Street Capital
Sausalito,
California
|
+$3.85M |
| 5 |
Millennium Management
New York
|
+$3.43M |
Top Sellers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
FCM
Farallon Capital Management
San Francisco,
California
|
-$13.2M |
| 2 |
CCI
Columbus Circle Investors
|
-$3.16M |
| 3 |
Fidelity Investments
Boston,
Massachusetts
|
-$2.44M |
| 4 |
Deutsche Bank
Frankfurt Am Main Ge,
Germany
|
-$1.92M |
| 5 |
Axa
Paris,
France
|
-$940K |
STML Hedge Fund Activity: Q4 2017 in Review
80 of the 4,409 institutional investors tracked by Wall St. Rank reported a position in Stemline Therapeutics, Inc. (STML) for Q4 2017, worth a combined $236M — up 65% from $143M a quarter earlier.
Buyers outnumbered sellers: 13 funds opened new STML positions and 11 closed out — a net gain of 2 holders — while 28 added to existing stakes and 22 trimmed.
The largest buyer was Consonance Capital Management, adding an estimated $30.1M. The largest seller was Farallon Capital Management, exiting entirely with an estimated $13.2M sold.
- 80 institutional investors held Stemline Therapeutics, Inc. (STML) as of Q4 2017, up from 79 in Q3 2017.
- Funds reported $236M of Stemline Therapeutics, Inc. stock for Q4 2017, up 65% quarter-over-quarter.
- 13 funds opened new Stemline Therapeutics, Inc. positions in Q4 2017 and 11 closed out, a net change of +2 holders.
- The largest Stemline Therapeutics, Inc. buyer in Q4 2017 was Consonance Capital Management, an estimated $30.1M added.
- The largest Stemline Therapeutics, Inc. seller in Q4 2017 was Farallon Capital Management, an estimated $13.2M sold.
Based on aggregated 13F filings for Q4 2017.